51420-32-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(4,5-dihydro-1H-imidazol-2-yl)hydrazine is used as a building block for the synthesis of various pharmaceutical compounds due to its unique chemical structure and reactivity. Its potential application in the treatment of cancer has been a significant area of interest, as it may contribute to the development of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(4,5-dihydro-1H-imidazol-2-yl)hydrazine is used as a precursor in the production of fungicides and insecticides. Its role in creating effective and targeted pest control solutions is valuable for agricultural applications, helping to protect crops and enhance overall yield.
Used in Research and Development:
1-(4,5-dihydro-1H-imidazol-2-yl)hydrazine is employed as a versatile intermediate in research and development for the synthesis of a wide array of nitrogen-containing compounds. Its unique properties make it an essential component in the creation of new chemical entities with potential applications in various fields, including materials science, pharmaceuticals, and agrochemicals.

InChI:InChI=1/C3H8N4/c4-7-3-5-1-2-6-3/h1-2,4H2,(H2,5,6,7)

Upstream product

• 20112-79-2 2-methylthioimidazoline 

Downstream Products

• 100862-87-1 2,5-dimethoxy-[1,4]benzoquinone-bis-imidazolidin-2-ylidenehydrazone 
• 102887-10-5 4,4'-propanediyldioxy-di-benzaldehyde-bis-imidazolidin-2-ylidenehydrazone 
• 103151-41-3 (4-imidazolidin-2-ylidenehydrazono-cyclohexa-2,5-dienylidenamino)-guanidine 
• 197358-39-7 2-benzyloxycarbonylamino-3-(2-{4-[N'-(4,5-dihydro-1H-imidazol-2-yl)-hydrazinocarbonylmethyl]-2,5-dioxo-imidazolidin-1-yl}-acetylamino)-propionic acid tert-butyl ester 
• 916652-91-0 C₂₄H₂₄N₈O 
• 61564-55-4 N-(4,5-Dihydro-1H-imidazol-2-yl)-N'-[1-(3,4-dimethoxy-phenyl)-meth-(Z)-ylidene]-hydrazine 

Relevant academic research and scientific papers

Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes

Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li

Aminoguanidine hydrazone derivatives as non-peptide NPFF1 receptor antagonists reverse opioid induced hyperalgesia

Neuropeptide FF receptors (NPFF1R and NPFF2R) and their endogenous ligand Neuropeptide FF have been shown previously to display anti-opioid properties and to play a critical role in the adverse effects associated with chronic administrations of opiates including the development of opioid-induced hyperalgesia and analgesic tolerance. In this work, we sought to identify novel NPFF receptors ligands by focusing our interest on a series of heterocycles as rigidified non-peptide NPFF receptor ligands, starting from already described aminoguanidine hydrazones (AGH's). Binding experiments and functional assays highlighted AGH 1n and its rigidified analog 2-amino-dihydropyrimidine 22e for in vivo experiments. As earlier shown with the prototypical dipeptide antagonist RF9, both 1n and 22e reduced significantly the long lasting fentanyl-induced hyperalgesia in rodents. Altogether these data indicate that AGH rigidification maintains nanomolar affinities for both NPFF receptors, while improving antagonist character towards NPFF1R.